

18. **Morgan TM, Welty CHJ, Funda VL, Lin DW, Wright.** Ductal Adenocarcinoma of the Prostate: Increased Mortality Risk and Decreased Serum Prostate Specific Antigen. *J Urol.* 2010; 184(6): 2303–7.
19. **Epstein JI, Allsbrook WCJ, Amin MB, Egevad LL, and the ISUP Grading Committee.** The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *Am J Surg Pathol* [Internet]. 2005; 29(9). Available from: https://journals.lww.com/ajsp/Full-text/2005/09000/The_2005_International_Society_of_Urological.15.aspx.
20. **Conteduca V, Oromendia C, Eng KW, et al.** Clinical features of neuroendocrine prostate cancer. *Eur J Cancer Oxf Engl* 1990. 2019; 121: 7–18.
21. **Aggarwal R, Huang J, Alumkal JJ, et al.** Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. *J Clin Oncol.* 2018; 36(24): 2492–503.
22. **Bluemn EG, Coleman IM, Lucas JM, et al.** Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. *Cancer Cell.* 2017; 32(4): 474–489.e6.
23. **Wang HT, Yao YH, Li BG.** Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis – A Systematic Review and Pooled Analysis. *J Clin Oncol.* 2014; 32(30): 3383–90.
24. **Park JW, Lee JK, Sheu KM, et al.** Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. *Science.* 2018; 362(6410): 91–5.
25. **Epstein JI, Amin MB, Beltran H, et al.** Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation. *Am J Surg Pathol.* 2014; 38(6): 756–67.
26. **Magers MJ, Iczkowski KA, Montironi R, et al.** MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. *Mod Pathol.* 2019; 32(11): 1666–74.